Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Background The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in …
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in …
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
BA Neuschwander-Tetri, R Loomba, AJ Sanyal… - genesis, 2014 - thelancet.com
Background The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in …
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in …
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
BA Neuschwander-Tetri, R Loomba, AJ Sanyal… - The Lancet, 2015 - infona.pl
The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a potent activator
of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal models of fatty …
of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal models of fatty …
[引用][C] Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
BA Neuschwander-Tetri, R Loomba, AJ Sanyal… - The Lancet, 2015 - cir.nii.ac.jp
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic
steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial | CiNii Research …
steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial | CiNii Research …
[HTML][HTML] Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
BA Neuschwander-Tetri, R Loomba, AJ Sanyal… - Lancet, 2015 - ncbi.nlm.nih.gov
Background The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in …
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in …
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial
BA Neuschwander-Tetri, R Loomba, AJ Sanyal… - The …, 2015 - pure.johnshopkins.edu
Background The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in …
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in …
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial
BA Neuschwander-Tetri, R Loomba, AJ Sanyal… - The …, 2015 - profiles.wustl.edu
Background The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in …
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in …
[引用][C] FARNESOID X NUCLEAR RECEPTOR LIGAND OBETICHOLIC ACID FOR NON-CIRRHOTIC, NON-ALCOHOLIC STEATOHEPATITIS (FLINT): A …
TBA NEUSCHWANDER - 2015 - sid.ir
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
BA Neuschwander-Tetri, R Loomba, AJ Sanyal… - The Lancet, 2015 - Elsevier
Background The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in …
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in …
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
BA Neuschwander-Tetri, R Loomba… - Lancet (London …, 2014 - europepmc.org
Background The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in …
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in …